Regulative effect of plant extract forskolin on atrial natriuretic peptide secretion

Ying Zhang,Jin Zheng-yuan,Liang Zhe-long,Jin Yuan-zhe,Xun Cui

DOI: https://doi.org/10.3321/j.issn:1673-8225.2006.39.041

2006-01-01

Abstract:AIM: To investigate the effect of the activation of adenylyl cyclase (AC) , extracted from plants, with forskolin on atrial natriuretic peptide (ANP) secretion as well as its mechanism. METHODS: The experiment was conducted in the Department of Physiology and Pathophysiology, Basic Medical School of Yanbian University in Jilin Province from September 2004 to September 2005. Twenty-six rabbits were selected and cut open the chest under anesthetization to remove the heart. The left auricle was isolated and fixed on the atrial perfusion system, which was given proper electric stimulation for beating. The following experiments were carried out on beating rabbit ventricles of in vitro perfusion:①When beating atria was stabilized, the control cycle (12 minutes as an experimental cycle) was followed by infusion of AC activator forskoline for three cycles (1 μmol/L).②After one control cycle, the L type Ca2+ channel blocker nifedipine (1 μmol/L) or nonspecific inhibitor protein kinases staurosporine was followed by forskolin for three cycles in the presence of the prior agents. The effects of forskolin on atrial stroke volume, and the efflux of cyclic adenosine monophosphate (cAMP) as well as ANP secretion were determined in real-time base by radioimmunoassay. RESULTS: ①Forskolin(1 μmol/L) obviously inhibited ANP secretion (P < 0.01) and remarkably increased atrial stroke volume and cAMP efflux (P < 0.01). Within certain range, the more the cAMP was the more the ANP secretion was inhibited, which were in a linear relationship (Y=-5.268 X+ 9.506, r2=0.971, P < 0.001).②Nifedipine (1 μmol/L) could not change the effect of forskolin on ANP secretion and cAMP (P < 0.01), whereas it could remarkably inhibited the atrial stroke volume (P < 0.01).③Integrated using of stauosporine and forskolin could markedly increase the cAMP efflux (P < 0.01) as well as remarkably inhibit ANP secretion (P < 0.01). However, the atrial stroke volume was not affected by increased cAMP, moreover, there was no significant difference between ANP secretion and staurosporine (the third cycle). CONCLUSION: Forskolin, the activating agent of camp, inhibits atrial ANP secretion mainly by protein kinase-dependent signal transduction pathway.